Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Cost-Analysis of Treatment of Patients With Acute Myeloid Leukemia Publisher



Alipour V1 ; Rad S2 ; Mezginejad F3 ; Jahangiri R4 ; Bagherzadeh R5 ; Nargesi S1 ; Mousavi SA2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Hematology, Oncology, and Hematopoietic Stem Cell Transportation Research Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
  4. 4. Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Foreign Languages, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran

Source: International Journal of Cancer Management Published:2021


Abstract

Background: Acute myeloid leukemia (AML) is the second common leukemia (5.18%) and the third deadliest leukemia in Iran. More-over, it is the fifth prevalent cancer in the world, which involves 8% of all cancers. Objectives: The aim of this study was to calculate direct medical and non-medical costs of AML in 2019. Methods: The present retrospective-descriptive analysis was conducted on 192 patients with AML aged 19 to 70 years from 2016 to 2018. The data were collected from hospital records and interviews with experts. The bottom-up micro-costing approach and payer perspective was considered for cost analysis status. The relationship of affective variables was investigated, using nonparametric tests, including Mann–Whitney and Kruskal–Wallis tests. Costs were divided into costs of diagnosis, hospitalization, medication, nursing, visit and consultation, operating room, and medical supplies. The data were described by mean ± standard deviation and reported by percentage and also analyzed by SPSS 11 software. Results: According to the findings, the average age of all patients was 43.91 years and 55.7% of the patients were male. The highest and the lowest diagnostic costs were associated with laboratory tests at $1656459.48 and ultrasound charges $4229.46, respectively. The total direct medical costs per patient were $1056624.78 with an average of $4846.90 and the cost of medication included 36% of the total costs. The direct medical and non-medical costs were $10485488.48 and $487522.87, respectively Conclusions: Costs of AML treatment were estimated to be $1056624.78. Finally, it can be concluded that the cost of AML in Iran is much cheaper than that compared to other countries and also due to hidden subsidies from the public sector, the payment from the patient’s pocket is very small. © 2021, Author(s).
Related Docs
1. The Economic Burden of Acute Myeloid Leukemia in Iran, Iranian Journal of Public Health (2022)
Experts (# of related papers)
Seyed Asadollah Mousavi (1)
Soroush Rad (1)